July 25, 2018 – By Lena Young
Schaper Benz & Wise Investment Counsel Inc increased its stake in Regeneron (REGN) by 18.23% based on its latest 2018Q1 regulatory filing with the SEC. Schaper Benz & Wise Investment Counsel Inc bought 2,369 shares as the companyâs stock declined 9.59% with the market. The institutional investor held 15,367 shares of the health care company at the end of 2018Q1, valued at $5.29 million, up from 12,998 at the end of the previous reported quarter. Schaper Benz & Wise Investment Counsel Inc who had been investing in Regeneron for a number of months, seems to be bullish on the $40.17B market cap company. The stock increased 1.79% or $6.56 during the last trading session, reaching $372.77. About 776,009 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has declined 35.54% since July 25, 2017 and is downtrending. It has underperformed by 48.11% the S&P500. Some Historical REGN News: 21/05/2018 â New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENTÂŽ (dupilumab) Improved Moderate-to-Sever; 01/05/2018 â REGENERON: EXPRESS SCRIPTS SELECTS PRALUENT EXCLUSIVE THERAPY; 12/03/2018 â Regeneron CEO Leonard Schleifer says the biotech firm will lower the price of Praluent so long as insurers increase access to patients; 21/05/2018 â New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENTÂŽ (dupilumab) Improved Moderate-to-Severe Asthma; 21/03/2018 â ALNYLAM â CO, REGENERON INTEND TO ENTER SEPARATE, 50-50 COLLABORATION TO FURTHER RESEARCH, CO-DEVELOP ANY THERAPEUTIC PRODUCT COMING FROM DISCOVERY; 19/03/2018 â REGENERON PHARMA-PHASE 3 TRIAL EVALUATING EYLEA INJECTION IN MODERATELY SEVERE TO SEVERE NON-PROLIFERATIVE DIABETIC RETINOPATHY MET PRIMARY ENDPOINT; 03/04/2018 â EMA to Review DUPIXENTÂŽ (dupilumab) as Potential Treatment for lnadequately Controlled Moderate-to-Severe Asthma; 11/05/2018 â Bayer: Second Indication for Eylea to Be Approved in China; 10/03/2018 â Regeneron, Sanofi Cut Heart Drugâs Price as Trial Disappoints; 19/03/2018 â NOVARTIS SAYS THE PATENT IN QUESTION DATES FROM 1997 AND IS CALLED âVECTOR FOR EXPRESSION OF A POLYPEPTIDE IN A MAMMALIAN CELLâ
Hallmark Capital Management Inc decreased its stake in Abbvie Inc (ABBV) by 11.29% based on its latest 2018Q1 regulatory filing with the SEC. Hallmark Capital Management Inc sold 3,612 shares as the companyâs stock declined 16.83% with the market. The institutional investor held 28,395 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $2.69M, down from 32,007 at the end of the previous reported quarter. Hallmark Capital Management Inc who had been investing in Abbvie Inc for a number of months, seems to be less bullish one the $138.60B market cap company. The stock increased 2.39% or $2.14 during the last trading session, reaching $91.54. About 7.97M shares traded. AbbVie Inc. (NYSE:ABBV) has risen 52.41% since July 25, 2017 and is uptrending. It has outperformed by 39.84% the S&P500. Some Historical ABBV News: 25/05/2018 â ASTRAZENECA PLC â IMFINZI MET SECOND PRIMARY ENDPOINT OF OVERALL SURVIVAL IN PHASE lll PACIFIC TRIAL; 11/04/2018 â MYLAN AND BIOCON SEEK TO ACCELERATE INTRODUCTION OF ADALIMUMAB; 25/04/2018 â ABBVIE INC â SIGNIFICANTLY MORE PATIENTS RECEIVING UPADACITINIB ACHIEVED ACR50, ACR70 AND CLINICAL REMISSION AT WEEK 12 COMPARED TO PLACEBO; 08/05/2018 â ONCOSEC EXPANDS RELATIONSHIP WITH MERCK, ANNOUNCES CLINICAL COLLABORATION TO EVALUATE COMBINATION OF IMMUNOPULSEÂŽ IL-12 AND KEYTRUDAÂŽ (PEMBROLIZUMAB) FOR TRIPLE NEGATIVE BREAST CANCER; 26/04/2018 â AbbVie unveils $7.5bn share buyback; 02/05/2018 â Positive Federal Legislation Could Lead to Exponential Growth in Marijuana and CBD Industry; 05/04/2018 â Samsung, Biogen Reach Deal With AbbVie to Sell Near Copy of Humira; 05/04/2018 â AbbVie Announces Global Resolution of HUMIRAÂŽ (adalimumab) Patent Disputes with Samsung Bioepis; 12/03/2018 â ADXS, $AZN.GB: $ADXS Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZenecaâs IMFINZIÂŽ (Durvalumab) â ! $AZN.GB $ADXS; 30/05/2018 â GILEAD SCIENCES INC â EPCLUSA IS FIRST PAN-GENOTYPIC HCV SINGLE TABLET REGIMEN (STR) APPROVED IN CHINA
Among 25 analysts covering Abbvie Inc (NYSE:ABBV), 9 have Buy rating, 3 Sell and 13 Hold. Therefore 36% are positive. Abbvie Inc had 98 analyst reports since July 21, 2015 according to SRatingsIntel. Jefferies maintained AbbVie Inc. (NYSE:ABBV) rating on Friday, September 15. Jefferies has âBuyâ rating and $10 target. The stock of AbbVie Inc. (NYSE:ABBV) earned âBuyâ rating by SunTrust on Wednesday, July 22. On Tuesday, February 23 the stock rating was upgraded by Citigroup to âBuyâ. The stock has âHoldâ rating by Credit Suisse on Wednesday, June 7. BMO Capital Markets maintained AbbVie Inc. (NYSE:ABBV) rating on Wednesday, May 23. BMO Capital Markets has âUnderperformâ rating and $78 target. BMO Capital Markets maintained the stock with âUnderperformâ rating in Friday, March 23 report. The stock has âBuyâ rating by UBS on Friday, October 23. BMO Capital Markets maintained the stock with âHoldâ rating in Wednesday, October 11 report. The stock of AbbVie Inc. (NYSE:ABBV) has âHoldâ rating given on Friday, June 1 by Piper Jaffray. The stock of AbbVie Inc. (NYSE:ABBV) earned âBuyâ rating by Jefferies on Monday, June 26.
Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on July, 27 before the open. They expect $1.97 EPS, up 38.73% or $0.55 from last yearâs $1.42 per share. ABBVâs profit will be $2.98 billion for 11.62 P/E if the $1.97 EPS becomes a reality. After $1.87 actual EPS reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 5.35% EPS growth.
More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: Fool.com which released: âWhat to Expect When AbbVie Reports Q2 Earningsâ on July 24, 2018, also 247Wallst.com with their article: âAmgen, Eli Lilly, Gilead and More Major Health Care Companies Reporting This Weekâ published on July 22, 2018, Bizjournals.com published: âPharma giant on hunt for half-million square feet on Peninsulaâ on July 13, 2018. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: Benzinga.com and their article: âAbbVieâs Stock Hit By Citron Tweetâ published on July 20, 2018 as well as Fool.comâs news article titled: âAbbVieâs Stock Is a Bargain After Falling 8% Last Weekâ with publication date: July 23, 2018.
Hallmark Capital Management Inc, which manages about $816.74 million and $822.22 million US Long portfolio, upped its stake in Amerisourcebergen Corp (NYSE:ABC) by 7,609 shares to 171,616 shares, valued at $14.80 million in 2018Q1, according to the filing. It also increased its holding in Exxon Mobil Corporation (NYSE:XOM) by 14,125 shares in the quarter, for a total of 213,752 shares, and has risen its stake in Chevron Corporation (NYSE:CVX).
Investors sentiment decreased to 0.7 in Q1 2018. Its down 0.10, from 0.8 in 2017Q4. It dropped, as 61 investors sold ABBV shares while 737 reduced holdings. 127 funds opened positions while 428 raised stakes. 1.06 billion shares or 0.67% less from 1.06 billion shares in 2017Q4 were reported. 17,734 were accumulated by First Natl Bank And Trust Of Newtown. Tiaa Cref Inv Limited Co invested in 8.12 million shares. Cape Cod Five Cents Bank reported 28,402 shares. Denver Invest Advsrs Llc reported 95,360 shares. Catawba Management Va holds 0.71% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 31,204 shares. Central Comml Bank Co reported 0.19% stake. Sterling Capital Lc holds 1.01% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 1.14 million shares. 5,137 are held by Parametrica Management Limited. Summit Financial Strategies stated it has 5,450 shares. 5,076 are owned by Keystone Financial Planning. Renaissance Technologies Ltd Co, a New York-based fund reported 1.76 million shares. Tealwood Asset, a Minnesota-based fund reported 101,950 shares. Suntrust Banks accumulated 811,042 shares. 2.21 million are owned by State Board Of Administration Of Florida Retirement Systems. Estabrook Cap Mgmt owns 0% invested in AbbVie Inc. (NYSE:ABBV) for 20,209 shares.
Since February 19, 2018, it had 2 insider purchases, and 10 insider sales for $26.21 million activity. RAPP EDWARD J had bought 1,013 shares worth $99,909 on Wednesday, June 20. On Wednesday, February 28 the insider Michael Robert A. sold $512,853. $8.31M worth of AbbVie Inc. (NYSE:ABBV) was sold by CHASE WILLIAM J on Wednesday, February 28. GONZALEZ RICHARD A also sold $976,084 worth of AbbVie Inc. (NYSE:ABBV) shares. ALBAN CARLOS sold $9.57M worth of AbbVie Inc. (NYSE:ABBV) on Wednesday, February 28. RICHMOND TIMOTHY J. sold $2.15 million worth of AbbVie Inc. (NYSE:ABBV) on Wednesday, February 28.
More notable recent Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news were published by: Seekingalpha.com which released: âHealthcare Dashboard â Updateâ on July 05, 2018, also Seekingalpha.com with their article: âReplimune set for $101M IPOâ published on July 14, 2018, Seekingalpha.com published: âRegeneron: The Catalystsâ on July 05, 2018. More interesting news about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were released by: Seekingalpha.com and their article: âOakmark Select Fund: Second Quarter 2018â published on July 11, 2018 as well as Seekingalpha.comâs news article titled: âRegeneronâs Price Implies Opportunityâ with publication date: July 09, 2018.
Among 33 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 12 have Buy rating, 1 Sell and 20 Hold. Therefore 36% are positive. Regeneron Pharmaceuticals Inc. had 130 analyst reports since July 28, 2015 according to SRatingsIntel. The company was downgraded on Monday, August 31 by Chardan Capital Markets. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has âHoldâ rating given on Wednesday, June 21 by Cowen & Co. Chardan Capital Markets downgraded the stock to âSellâ rating in Monday, January 25 report. The firm earned âBuyâ rating on Monday, August 31 by RBC Capital Markets. The company was maintained on Wednesday, August 5 by UBS. The firm earned âBuyâ rating on Monday, July 16 by Argus Research. Leerink Swann maintained the stock with âBuyâ rating in Monday, June 12 report. The rating was maintained by BMO Capital Markets with âHoldâ on Thursday, August 3. The company was maintained on Friday, May 4 by BMO Capital Markets. The stock has âEqual-Weightâ rating by Morgan Stanley on Friday, May 4.
Schaper Benz & Wise Investment Counsel Inc, which manages about $585.75M and $675.15M US Long portfolio, decreased its stake in Intel (NASDAQ:INTC) by 15,270 shares to 337,825 shares, valued at $17.59 million in 2018Q1, according to the filing. It also reduced its holding in Varian Medical Systems (NYSE:VAR) by 4,390 shares in the quarter, leaving it with 110,741 shares, and cut its stake in Alphabet (Google) A.
Investors sentiment decreased to 1.05 in 2018 Q1. Its down 0.12, from 1.17 in 2017Q4. It dived, as 70 investors sold REGN shares while 158 reduced holdings. 71 funds opened positions while 169 raised stakes. 69.33 million shares or 0.23% more from 69.17 million shares in 2017Q4 were reported. Tekla Cap Management Llc holds 139,560 shares. 185 are held by Optimum Inv Advsr. Neuberger Berman Gp Inc Ltd Liability holds 294,811 shares or 0.12% of its portfolio. Dnb Asset Mngmt As holds 0% or 26,400 shares in its portfolio. Lumina Fund Management Limited Company, a New York-based fund reported 13,000 shares. Oregon Public Employees Retirement Fund owns 18,845 shares. Thrivent Financial For Lutherans has 0% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Polen Capital Management Ltd Liability Corp owns 1.42M shares or 3.47% of their US portfolio. Winslow Evans And Crocker invested in 0% or 1,066 shares. Balyasny Asset Mgmt Ltd Liability Com holds 0.25% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 174,174 shares. Franklin Resources holds 0.13% or 767,860 shares in its portfolio. Jefferies Grp Incorporated Limited Liability stated it has 0% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Dsm Prns stated it has 1.36% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). The Michigan-based Comerica Secs has invested 0.04% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Van Eck Associates Corp reported 61,064 shares.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.